Skeletal muscle derived stem cells for myocardial repair

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 3, 2007, Pages 205-213

  Haider, Husnain K ^a   Ye, Lei ^b   Ashraf, Muhammad ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cardiac; Cells; Heart; Myocardium; Skeletal myoblasts

Indexed keywords

ADENOVIRUS VECTOR; AMIODARONE; ANGIOPOIETIN 1; CARDIOTROPHIN 1; CONNEXIN 43; CYCLIN A; CYCLOSPORIN; CYTOKINE; GROWTH FACTOR; HEAT SHOCK PROTEIN; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS; VASCULOTROPIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIOVERSION; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; DEFIBRILLATION; DRUG SAFETY; EMBRYONIC STEM CELL; EX VIVO STUDY; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION; GRAFT REJECTION; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; MUSCLE CELL; MUSCLE REGENERATION; NONHUMAN; NONVIRAL GENE THERAPY; ONCOGENE; OUTCOME ASSESSMENT; PATIENT SAFETY; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SCAR FORMATION; SKELETAL MUSCLE; STEM CELL GENE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT DURATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ARRHYTHMIAS, CARDIAC; COMBINED MODALITY THERAPY; GENE THERAPY; HEART FAILURE; HUMANS; MYOBLASTS, SKELETAL; MYOCARDIAL INFARCTION; MYOCARDIUM; STEM CELL TRANSPLANTATION;

EID: 36749003419     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007782418955     Document Type: Review

References (112)

1. Arjomand H, Cohen M, Ezekowitz MD. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease. J Invasive Cardiol 2004; 16: 271-278.
2. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59: 551-571.
3. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001; 344: 1750-1757.
4. Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA, Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci USA 1998; 95: 8801-8805.
5. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005; 85: 1373-1416.
6. Dawn B, Guo Y, Rezazadeh A, et al. Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricuiar function. Circ Res 2006; 98: 1098-1105.
7. Weisel RD, Li RK, Mickle DA, Yau TM. Cell transplantation comes of age. J Thorac Cardiovasc Surg 2001; 121: 835-836.
8. Mickle, D., Li, R., Weisel, RD.: US20070031389A1 (2007).
9. Chaudhry, H.W., Wolgemuth, D.J.: US20070178075A1 (2007).
10. Soonpaa MH, Koh GY, Pajak L, et al. Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. J Clin Invest 1997; 99: 2644-2654.
11. Engelmann GL, Birchenall-Roberts MC, Ruscetti FW, Samarel AM. Formation of fetal rat cardiac cell clones by retroviral transformation: retention of select myocyte characteristics. J Mol Cell Cardiol 1993; 25: 197-213.
12. Rosenthal N, Tsao L. Helping the heart to heal with stem cells. Nat Med 2001; 7: 412-13.
13. Chande M. Stem cells get to the heart of the matter. Lancet 2001; 357: 1099.
14. Anversa, P.: US20060239983A1 (2006).
15. Lattanzi L, Salvatori G, Coletta M, et al. High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest 1998; 101: 2119-2128.
16. Murry CE, Kay MA, Bartosek T, Hauschka SD, Schwartz SM. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. J Clin Invest 1996; 98: 2209-2217.
17. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-436.
18. Condorclli G, Borello U, De Angelis L, et al. Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: implications for myocardium regeneration. Proc Natl Acad Sci USA 2001; 98: 10733-10738.
19. Watanabe E, Smith DM Jr, Delcarpio JB, et al. Cardiomyocyte transplantation in a porcine myocardial infarction model. Cell Transplant 1998; 7: 239-246.
20. Koh GY, Soonpaa MH, Klug MG, Field LJ. Long-term survival of AT-I cardiomyocyte grafts in syngeneic myocardium. Am J Physiol 1993; 264: H1727-1733.
21. Muller-Ehmsen J, Whittaker P, Kloner RA, et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol 2002; 34: 107-116.
22. Yoo KJ, Li RY, Weisel RD, Mickle DA, Li G, Yau TM. Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann Thorac Surg 2000; 70: 859-865.
23. Li RK, Jia ZQ, Weisel RD, Merante F, Mickle DA. Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J Mol Cell Cardiol 1999; 31: 513-522.
24. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001; 105: 369-377.
25. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697-705.
26. Goodell MA, Jackson KA, Majka SM, et al. Stem cell plasticity in muscle and bone marrow. Ann N Y Acad Sci 2001; 938: 208-18; discussion 218-220.
27. Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109: 1543-1549.
28. Tse HF, Kwong YL, Chan K Lo G, He CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361: 47-49.
29. Stamm C, Kleine HD, Westphal B, et al. CABG and bone marrow stem cell transplantation after myocardial infarction. Thorac Cardiovasc Surg 2004; 52: 152-158.
30. Leor J, Gerecht-Nir S, Cohen S, et al. Human embryonic stem cell transplantation to repair the infarcted. myocardium. Heart 2007; 93(10): 1278-1284.
31. Rufaihah AJ, Haider HK, Heng BC, et al. Directing endothelial differentiation of human embryonic stem cells via transduction with an adenoviral vector expressing the VEGF(165) gene. J Gene Med 2007; 9: 452-461.
32. Behfar A, Perez-Terzic C, Faustino RS, et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med 2007; 204: 405-420.
33. Davidson, B.P., Graichen, R.E.: WO07070964A1 (2007).
34. Haider H, Tan AC, Aziz S, Chachques JC, Sim EK. Myoblast transplantation for cardiac repair: a clinical perspective. Mol Ther 2004; 9: 14-23.
35. Marclli D, Ma F, Chin RC. Satellite cell implantation for neomyocardial regeneration. Transplant Proc 1992; 24: 2995.
36. Khan M, Kutala VK, Vikram DS, et al. Skeletal myoblasts transplanted in the ischemic myocardium enhance in situ oxygenation and recovery of contractile function. Am J Physiol Heart Circ Physiol 2007; 27: H2129-H2139.
37. Kupussamy, P., Kutala, V.K., Zweier, J.L., Kwiatkowski, P.: US20070041909A1 (2007).
38. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998; 4: 929-933.
39. Atkins BZ, Lewis CW, Kraus WE, Hutcheson KA, Glower DD, Taylor DA. Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells in situ. Ann Thorac Surg 1999; 67: 124-129.
40. Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001; 103: 1920-1927.
41. Tambara K, Sakakibara Y, Sakaguchi G, et al. Transplanted skeletal myoblasts can fully replace the infarcted myocardium when they survive in the host in large numbers. Circulation 2003; 108 (Suppl 1): II 259-263.
42. Soykan, O., Donovan, M.G.: US20070106201A1 (2007).
43. Stegemann, J.P., Lord, E.J.: US20070116680A1 (2007).
44. Ghostine S, Carrion C, Souza LC, et al. Long-term efficacy of myoblast transplantation on regional structure and function after myocardial infarction. Circulation 2002; 106:1131-136.
45. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 1996; 98: 2512-2523.
46. Reinecke H, Poppa V, Murry CE. Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting. J Mol Cell Cardiol 2002; 34: 241-249.
47. Ohno N, Fedak PW, Weisel RD, Mickle DA, Fujii T, Li RK. Transplantation of cryopreserved muscle cells in dilated cardiomyopathy: effects on left ventricular geometry and function. J Thorac Cardiovasc Surg 2003; 126: 1537-1548.
48. Ott HC, Kroess F, Bonaros N, et al. Intramyocardial microdepot injection increases the efficacy of skeletal myoblast transplantation. Eur J Cardiothorac Surg 2005; 27: 1017-1021.
49. Scorsin M, Hagege A, Vilquin JT, et al. Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg 2000; 119: 1169-1175.
50. Agbulut O, Vandervelde S, Al Attar N, et al. Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. J Am Coll Cardiol 2004; 44: 458-463.
51. Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet 2001; 357: 279-280.
52. Menasche P, Hagege AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003; 41: 1078-1083.
53. Hagege AA, Carrion C, Menasche P, et al. Viability and differentiation of autologous skeletal myroblast grafts in ischaemic cardiomyopathy. Lancet 2003; 361: 491-492.
54. Pagani FD, DerSimonian H, Zawadzka A, et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol 2003; 41: 879-888.
55. Smits PC, van Geuns RJ, Poldermans D, et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol 2003; 42: 2063-2069.
56. Haider H, Jiang SJ, Lei Y, Law PK, Sim EKW. Effectiveness of transient immunosuppression using cyclosporine for xenomyoblast transplantation for cardiac repair. Transplant Proc 2004; 36: 232-235.
57. Haider H, Ye L, Jiang S, et al. Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J Mol Med 2004; 82: 539-549.
58. Law PK, Fang G, Chua F, Kakuchaya T, Bockeria LA. First-in-Man myoblast allografts for heart degeneration. Int J Med Implants Devices 2003; 1: 100-155.
59. Sim EK, Haider HK, Aziz S, Ooi OC, Law PK. Myoblast transplantation on the beating heart. Int Surg 2005; 90: 148-150.
60. Hagege AA, Marolleau JP, Vilquin JT, et al. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation 2006; 114: 1108-113.
61. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004; 428: 664-668.
62. Law, P.: EP1497410A2 (2005).
63. Iijima Y, Nagai T, Mizukami M et al. Beating is necessary for transdifferentiation of skeletal muscle-derived cells into cardiomyocytes. FASEB J 2003; 17: 1361-1363.
64. Reinecke H, Minami E, Poppa V, Murry CE. Evidence for fusion between cardiac and skeletal muscle cells. Circ Res 2004; 94: e56-60.
65. Rubart M, Soonpaa MH, Nakajima H, Field LJ. Spontaneous and evoked intracellular calcium transients in donor-derived myocytes following intracardiac myoblast transplantation. J Clin Invest 2004; 114: 775-783.
66. Chancellor, M., Huard, J.: EP1113807A2 (2001).
67. Ye L, Haider H, Jiang S, et al. Angiopoietin-1 for myocardial angiogenesis: a comparison between delivery strategies. Eur J Heart Fail 2007; 9: 458-465.
68. Koh GY, Kim SJ, Klug MG, Park K, Soonpaa MH, Field LJ. Targeted expression of transforming growth factor-beta 1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J Clin Invest 1995; 95: 114-121.
69. Ye L, Haider H, Jiang S, et al. Reversal of myocardial injury using genetically modulated human skeletal myoblasts in a rodent cryoinjured heart model. Eur J Heart Fail 2005; 7: 945-952.
70. Yau TM, Kim C, Li G, et al. Enhanced angiogenesis with multimodal cell-based gene therapy. Ann Thorac Surg 2007; 83: 1110-1119.
71. Ye L, Haider H, Jiang S, et al. Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin-1. Eur J Heart Fail 2007; 9: 15-22.
72. Ehnadbouh I, Haider H, Jiang S, Idris NM, Lu G, Ashraf M. Ex vivo delivered stromal cell-derived factor-1 alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium. J Mol Cell Cardiol 2007; 42: 792-803.
73. Pouzet B, Vilquin JT, Hagege AA, et al. Intramyocardial transplantation of autologous myoblasts: can tissue processing be optimized? Circulation 2000; 102: III 210-215.
74. Herreros J, Prosper F, Perez A, et al. Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur Heart J 2003; 24: 2012-2020.
75. Chachques JC, Herreros J, Trainin J, et al. Autologous human serum for cell culture avoids the implantation of cardioverter-defibrillators in cellular cardiomyoplasty. Int J Cardiol 2004; 95 (Suppl 1): S29-33.
76. Yaeger, P., Stewart, J.D., Wentworth, B.M.: US20070086987A1 (2007).
77. Pouzet B, Vilquin JT, Hagege AA, et al. Factors affecting functional outcome after autologous skeletal myoblast transplantation. Ann Thorac Surg 2001; 71: 844-850; discussion 850-851.
78. Qu Z, Balkir L, van Deutekom JC, Robbins PD, Pruchnic R, Huard J. Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 1998; 142: 1257-1267.
79. Merly F, Huard C, Asselin I, Robbins PD, Tremblay JP. Anti-inflammatory effect of transforming growth factor-beta1 in myoblast transplantation. Transplantation 1998; 65: 793-799.
80. Guerette B, Asselin I, Vilquin JT, Roy R, Tremblay JP. Lymphocyte infiltration following allo- and xenomyoblast transplantation in mdx mice. Muscle Nerve 1995; 18: 39-51.
81. Skuk D, Caron N, Goulet M, Roy B, Espinosa F, Tremblay JP. Dynamics of the early immune cellular reactions after myogenic cell transplantation. Cell Transplant 2002; 11: 671-681.
82. So CY, Chong KY, Chen J, Ryter S, Khardori R, Lai CC. A physiologically relevant hyperthermia selectively activates constitutive hsp70 in H9c2 cardiac myoblasts and confers oxidative protection. J Mol Cell Cardiol 1999; 31: 845-855
83. Suzuki V, Smolenski RT, Jayakumar J, Murtuza B, Brand NJ, Yacoub MH. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation 2000; 102: III 216-221.
84. Hodgetts SI, Grounds MD. Complement and mynblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5. Immunol Cell Biol 2001; 79: 231-239.
85. Pavlath GK, Rando TA, Blau HM. Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibers. J Cell Biol 1994; 127: 1923-1932.
86. Irintchev A, Zweyer M, Wernig A. Cellular and molecular reactions in mouse muscles after myoblast implantation. J Neurocytol 1995; 24: 319-331.
87. Murry, C., Laflamme, M.A.: US20070166288A1 (2007).
88. Gurke L, Mattei A, Chaloupka K, et al. Mechanisms of ischemic preconditioning in skeletal muscle. J Surg Res 2000; 94: 18-27.
89. Niagara MI, Haider H, Jiang S, Ashraf M. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyo-genesis via release of paracrine factors in the infarcted heart. Circ Res 2007; 100: 545-555.
90. Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Charpak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host Proc Natl Acad Sci USA 2003; 100: 7808-7811.
91. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol 2000; 149: 731-740.
92. Dib N, Michler RE, Pagani FD, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation 2005; 112: 1748-1755.
93. Siminiak T, Grygielska B, Jerzykowska O, et al. Autologous bone marrow stem cell transplantation in acute myocardial infarction-report of two cases. Kardiol Pol 2003; 59: 502-510.
94. Fouts & Fernandes B, Mal N, Liu J, Laurita KR. Electrophysiological consequence of skeletal myoblast transplantation in normal and infarcted canine myocardium. Heart Rhythm 2006; 3: 452-461.
95. Suzuki K, Brand NJ, Allen S, et al. Overexpression of connexin 43 in skeletal myoblasts: Relevance to cell transplantation to the heart. J Thorac Cardiovasc Surg 2001; 122: 759-766.
96. Gutstein DE, Morley GE, Fishman GI. Conditional gene targeting of connexin43: exploring the consequences of gap junction remodeling in the heart. Cell Commun Adhes 2001; 8: 345-348.
97. Toh R, Kawashima S, Kawai M, et al. Transplantation of cardiotrophin-1-expressing myoblasts to the left ventricular wall alleviates the transition from compensatory hypertrophy to congestive heart failure in Dahl salt-sensitive hypertensive rats. J Am Coll Cardiol 2004; 43: 2337-2347.
98. Sugimoto T, Inui K, Shimazaki Y. Gene therapy for myocardial angiogenesis: with direct intramuscular gene transfer of naked deoxyribonucleic acid encoding vascular endothelial growth factor and cell transplantation of vascular endothelial growth factor transfected H9c2 myoblast Jpn J Thorac Cardiovasc Surg 2003; 51: 192-197.
99. Kim EJ, Li RK, Weisel RD, et al. Angiogenesis by endothelial cell transplantation. J Thorac Cardiovasc Surg 2001; 122: 963-971.
100. Ruhparwar A, Tebbenjohanns J, Niehaus M, et al. Transplanted fetal cardiomyocytes as cardiac pacemaker. Eur J Cardiothorac Sing 2002; 21: 853-857.
101. Huwer H, Winning J, Vollmar B, et al. Long-term cell survival and hemodynamic improvements after neonatal cardiomyocyte and satellite cell transplantation into heated myocardial cryoinfarcted lesions in rats. Cell Transplant 2003; 12: 757-767.
102. Skobel E, Schuh A, Schwarz ER, et al. Transplantation of fetal cardiomyocytes into infarcted rat hearts results in long-term functional improvement. Tissue Eng 2004; 10: 849-864.
103. Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann N Y Acad Sci 2001; 938: 221-229.
104. Jiang S, Haider H, Idris NM, Salim A, Ashraf M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 2006; 99: 776-784.
105. Kudo K Wang Y, Wani MA, Xu M, Ayub A, Ashraf M. Implantation of bone marrow stem cells reduces the infarction and fibrosis in ischemic mouse heart. J Mol Cell Cardiol 2003; 35: 1113-1119.
106. Robinson SW, Cho PW, Levitsky HI, et al. Arterial delivery of genetically labelled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts. Cell Transplant 1996; 5: 77-91.
107. Chazaud B, Hittinger L, Sonnet C, et al. Endoventricular porcine autologous myoblast transplantation can be successfully achieved with minor mechanical cell damage. Cardiovasc Res 2003; 58: 444-450.
108. Suzuki K, Murtuza B, Suzuki N, Smolenski RT, Yacoub MH. Intacoronary infusion of skeletal myoblasts improves cardiac finiction in doxorubicin-induced heart failure. Circulation 2001; 104: I 213-217.
109. Rajnoch C, Chachques JC, Berrebi A, Bruneval P, Benoit MO, Carpenter A. Cellular therapy reverses myocardial dysfunction. J Thorac Cardiovasc Surg 2001; 121: 871-878.
110. Zhang F, Chen Y, Yang Z, et al. Cellular cardiomyoplasty for a patient with heart failure. Cardiovasc Radiat Med 2003; 4: 43-46.
111. Chachques JC, Acar C, Herreros J, et al. Cellular cardiomyoplasty: clinical application. Am Thorac Surg 2004; 77: 1121-1130.
112. Siminiak T, Kalawski R, Fiszer D, et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: phase I clinical study with 12 months of follow-up. Am Heart J 2004; 148: 531-537.